CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 108 enrolled
Drug / intervention
TRI102 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02083783
NCT02083783Phase 3Completed
CompareCT.gov

TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study

Tris Pharma, Inc.·interventional·Posted Mar 11, 2014·Updated Aug 26, 2020

In Brief

A Phase 3 clinical trial evaluating TRI102 and Placebo for Attention Deficit Disorder With Hyperactivity. Completed, enrolled 108 participants across 5 sites.

Detailed Summary

The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Disorder With Hyperactivity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 11, 2014
Enrollment StartMar 1, 2014
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.3 years ago

Interventions

TRI102drug

formulation containing active moiety (amphetamine)

Placeboother

formulation without active moiety